Genetic glitch can predict response to new class of cancer drugs
May 29, 2015 at 14:00 PM EDT
CHICAGO, May 29 (Reuters) - Patients with colon and other cancers who have a specific defect in genes needed for DNA repair are far more likely to respond to a new class of drugs such as Merck & Co's Keytruda, which enlist the immune system to attack tumors, a new study has shown.